AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

“PD-1 is a co-inhibitory receptor found preferentially on activated T cells. We look forward to sharing for rosnilimab, an eplete and agonist targeting PD-1+ T cells, top-line Phase IIb ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...

Its most advanced project is MB272, an agonist of B- and T-lymphocyte attenuator (BTLA) which recently started phase 1 testing, and it has a PD-1 agonist called MB151 in late preclinical development.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by ...

NLY01, a long-acting GLP-1 agonist, recently completed a 36-week ... patients newly diagnosed with PD. Collaborative efforts to extend these findings to the treatment of other chronic and ...